1. Home
  2. INDP vs AVK Comparison

INDP vs AVK Comparison

Compare INDP & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$3.18

Market Cap

438.4M

Sector

Health Care

ML Signal

N/A

Logo Advent Convertible and Income Fund

AVK

Advent Convertible and Income Fund

N/A

Current Price

$10.03

Market Cap

482.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
AVK
Founded
2000
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
438.4M
482.5M
IPO Year
2021
2003

Fundamental Metrics

Financial Performance
Metric
INDP
AVK
Price
$3.18
$10.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 211.2K
150.6K
Earning Date
11-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$9.98
52 Week High
$5.96
$13.28

Technical Indicators

Market Signals
Indicator
INDP
AVK
Relative Strength Index (RSI) 50.79 28.20
Support Level $2.17 N/A
Resistance Level $3.71 $11.12
Average True Range (ATR) 0.34 0.23
MACD -0.02 -0.05
Stochastic Oscillator 51.34 5.83

Price Performance

Historical Comparison
INDP
AVK

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About AVK Advent Convertible and Income Fund

Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.

Share on Social Networks: